Coregulator Control of Androgen Receptor Action by a Novel Nuclear Receptor-binding Motif*
- Katja Jehle‡1,
- Laura Cato§,¶1,
- Antje Neeb‡,
- Claudia Muhle-Goll‖,
- Nicole Jung‖,
- Emmanuel W. Smith**,
- Victor Buzon‡‡,
- Laia R. Carbó‡‡,
- Eva Estébanez-Perpiñᇇ,
- Katja Schmitz§§,
- Ljiljana Fruk¶¶,
- Burkhard Luy‖,
- Yu Chen**,
- Marc B. Cox‖‖,
- Stefan Bräse‡,‖,
- Myles Brown§,¶ and
- Andrew C. B. Cato‡2
- From the ‡Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, 76344 Eggenstein-Leopoldshafen, Germany,
- the §Division of Molecular and Cellular Oncology, Department of Medical Oncology, and
- ¶Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215,
- the ‖Institute of Organic Chemistry, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany,
- the **Department of Molecular Medicine, College of Medicine, University of South Florida, Tampa, Florida 33612,
- the ‡‡Institute of Biomedicine, Department of Biochemistry and Molecular Biology, University of Barcelona, 08028 Barcelona, Spain,
- the §§Clemens-Schöpf-Institut für Organische Chemie und Biochemie, Technische Universität Darmstadt, 64287 Darmstadt, Germany,
- the ¶¶Deutsche Forschungsgemeinschaft Center for Nanostructures, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany, and
- the ‖‖Border Biomedical Research Center and Department of Biological Sciences, University of Texas, El Paso, Texas 79968
- ↵2 To whom correspondence should be addressed: Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, 76344 Eggenstein-Leopoldshafen, Germany. Tel.: 49-721-608-22146; Fax: 49-721-608-23354; E-mail: andrew.cato{at}kit.edu.
-
↵1 Both authors contributed equally to this work.
Abstract
The androgen receptor (AR) is a ligand-activated transcription factor that is essential for prostate cancer development. It is activated by androgens through its ligand-binding domain (LBD), which consists predominantly of 11 α-helices. Upon ligand binding, the last helix is reorganized to an agonist conformation termed activator function-2 (AF-2) for coactivator binding. Several coactivators bind to the AF-2 pocket through conserved LXXLL or FXXLF sequences to enhance the activity of the receptor. Recently, a small compound-binding surface adjacent to AF-2 has been identified as an allosteric modulator of the AF-2 activity and is termed binding function-3 (BF-3). However, the role of BF-3 in vivo is currently unknown, and little is understood about what proteins can bind to it. Here we demonstrate that a duplicated GARRPR motif at the N terminus of the cochaperone Bag-1L functions through the BF-3 pocket. These findings are supported by the fact that a selective BF-3 inhibitor or mutations within the BF-3 pocket abolish the interaction between the GARRPR motif(s) and the BF-3. Conversely, amino acid exchanges in the two GARRPR motifs of Bag-1L can impair the interaction between Bag-1L and AR without altering the ability of Bag-1L to bind to chromatin. Furthermore, the mutant Bag-1L increases androgen-dependent activation of a subset of AR targets in a genome-wide transcriptome analysis, demonstrating a repressive function of the GARRPR/BF-3 interaction. We have therefore identified GARRPR as a novel BF-3 regulatory sequence important for fine-tuning the activity of the AR.
- Androgen Receptor
- Chromatin Immunoprecipitation (ChiP)
- Gene Expression
- Ligand-binding Protein
- Prostate Cancer
- Activation Function-2 (AF-2)
- Androgen Receptor Ligand-binding Domain (AR-LBD)
- Bag-1L
- Binding Function-3 (BF-3)
- Nuclear Receptors
Footnotes
-
↵* This work was supported, in whole or in part, by National Institutes of Health Grants 5 G12 RR008124 (from the National Center for Research Resources) and 8 G12 MD007592 (from the National Institute on Minority Health and Health Disparities) (to M. B. C.) and 1P01CA163227–01A1 (Androgen Receptor Action in Castration Resistant Prostate Cancer) and P50CA090381 (Prostate Cancer SPORE) (to M. B.). This work was also supported by grants from the KIT start-up funds and Deutsche Krebshilfe Grant 110237 (to A. C. B. C.) and Cancer Prevention and Research Institute of Texas Grant RP110444-P2 (to M. B. C.).
-
↵
This article contains supplemental Tables 1–3.
-
Microarray data have been submitted to the Gene Expression Omnibus (GEO) repository under the accession number GSE51524.
- Received November 14, 2013.
- Revision received February 11, 2014.
- © 2014 by The American Society for Biochemistry and Molecular Biology, Inc.











